Cytosorbents (CTSO) Assets Average (2011 - 2026)

Cytosorbents has reported Assets Average for 15 years, with the latest figure at $42.4 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 13.66% year-over-year to $42.4 million; the trailing twelve-month figure through Mar 2026 stood at $42.4 million (down 13.66% YoY), and the FY2025 full-year result was $45.8 million, down 8.75% from the prior year.
• Assets Average for Q1 2026 stood at $42.4 million, down from $45.0 million in the prior quarter.
• The five-year high for Assets Average was $86.4 million in Q1 2022, with the low at $42.4 million in Q1 2026.
• Historically, Assets Average has averaged $55.3 million across 5 years, with a median of $50.2 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average slumped 32.01% — and 2024, when it advanced 1.21%.
• Cytosorbents' Assets Average stood at $62.8 million in 2022, then declined by 19.9% to $50.3 million in 2023, then fell by 5.33% to $47.6 million in 2024, then retreated by 5.51% to $45.0 million in 2025, then declined by 5.77% to $42.4 million in 2026.
• The last three Assets Average figures came in at $42.4 million (Q1 2026), $45.0 million (Q4 2025), and $46.9 million (Q3 2025), per Business Quant data.